The following quotes are from technical experts at the U.S. Dept. of Energy (DOE) and the National Cancer Institute (NIH-NCI) that evaluated the UFT and PPS technology in their reviews of the most recent Integrated Sensors SBIR Phase-I and Phase-II proposals from DOE in 2019 and 2020, and the most recent SBIR Phase-II proposal from NIH in 2016, all of which resulted in SBIR Awards.

Phase-II DOE reviewers at the Office of Nuclear Physics (April 2020):

“This Phase II proposal strongly builds on the successful completion of a Phase I project in which the goals have been completed and some estimated performance characteristics have been exceeded.

The proposed beam monitoring system could have transformational impact in the area of proton beam therapy, especially in its FLASH form. Its societal impact would be huge.

The total cost of this R&D effort is justified by the transformative improvement in beam monitoring at accelerator facilities. When considering the potential for an even larger benefit to society through enabling next-generation particle beam therapy, this proposal stands out as being a particularly worthwhile use of taxpayer funds.

If successful, this proposal has remarkable upside.”

Phase-I DOE reviewer at the Office of Nuclear Physics (Jan 2019):

“This [proposal] is aimed to develop novel high-performance [redacted] material for detecting and counting charged particles. Because of its unique properties, the material undoubtedly has great potentials to move the current state-of-the-art charged particle detector technology to a new level.

This is the first group to design a particle beam detection system based on this material.

As stated in the proposal, a preliminary evaluation has generated significant interest at MSU-NSCL/FRIB and the LHC-ATLAS detector group at the University of Michigan (UM), with both groups having committed to working with I-S as subcontractors on the proposed program. Interest has also been expressed at JLab and BNL which have provided Letters of Support.

Both the University of Michigan and Michigan State University, participating in this project as subcontractors, are the top research centers specialized in radiation detection and nuclear instrumentation.

It is clearly beneficial for DOE-NP that one of the tasks of the proposed work focus on improving beam quality primarily for high-energy experiments and especially for exotic beams, as well as reducing the time spent on beam tuning/development and therefore lower operational costs and more time for experiments.

If successful, the proposed technology will provide a new type of material and a novel beam monitor to enable enhanced particle accelerator performance. Nuclear and high energy physics, high-tech industries and medical treatment of cancer can all benefit by this technology.”

Phase-II NIH reviewers at the National Cancer Institute (Jan 2016):

Summary of Reviewers Discussion:  “This Phase II application proposes to develop a new detector, the plasma panel sensor (PPS), which has the potential to remove the barriers of existing detectors. As the interest in proton radiotherapy continues to grow, these detectors have potential applications for both imaging and beam monitoring. The applicant is well experienced in chemical engineering and also an expert in the proposed research area. His team of physicists and engineers has complementary expertise, and they are well positioned to carry out the proposed studies. The applicant has successfully completed the Phase 1 studies and is now seeking to expand in this Phase II application, with plans for taking it further with Phase III funding commitment by a commercial company. Reviewers agree that the strategy and objectives described herein are appropriate and sound. The new research plan has the key description of relevant PPS detector attributes and experiments, along with the needed simulation studies. Furthermore, the application as written includes a detail commercialization plan. Despite the minor concerns regarding experimental details from some reviewers, the committee members agree that the proposed studies are of high clinical significance, with high likelihood of success to lead to enabling technology for particle beam monitoring and imaging. Overall, the enthusiasm is high among the committee members for this outstanding to exceptional Phase II application from a well-established investigator with impressive track record.”